Healthcare Capital & Connections Summit


Important Update

HCCS 2020 has been postponed. Please read details below.

Below was the proposed agenda for the 2020 summit. The event is currently postponed, we will announce a new date in the coming months. Please subscribe for updates. 

  1. 2020 Summit Agenda


    Monday, March 23, 2020

    2:00 - 5:00 Pre-Conference Session: China 101: Navigating Market Expansion
    6:30 - 8:00 HCCS Opening Reception and Early Registration

    Tuesday, March 24, 2020

    9:00 - 9:15 Welcome and Opening Remarks
    9:15 - 9:45 China Healthcare 2020: The Global Outlook
    9:45 - 11:15 Navigating the Public Markets - Where and When to List
    11:15 - 11:30 Break
    11:30 - 12:00 Impact of U.S. Foreign Policy, Trade Policy & Security on Cross-Border Deals
    12:00 - 1:00 Lunch
    1:00 - 2:30 1:1 Meetings Available through MeetingMojo
    1:00 - 1:05 Afternoon Opening Remarks
    1:05 - 2:30 Global Strategy - Sharing Best Practices (Sub-Sector Tracks)
      1:05 - 1:30  Biopharma: Perspectives on Operating Cross-Border
      1:30 - 2:00  HealthTech: How US and China Venture Capital Firms See the Sector
      2:00 - 2:30  Medtech: Cross-Border Commercial Strategies
    2:30 - 2:45 Break
    2:45 - 3:30 James McGregor Remarks and Fireside Chat
    3:30 - 4:15 Tales from the Front Line: Investment and Cross-Border Deals in China
    4:15 - 5:00 Partnering in the Global Market: Cross-Border Challenges and Opportunities
    5:00 - 5:15 Closing Remarks
    6:30 - 8:30 HCCS Dinner


  2. 2020 Speakers


    Katherine Anderson
    Head of Life Science & Healthcare Relationship Banking
    Silicon Valley Bank

    Katherine Andersen is head of the Life Science & Healthcare Relationship Banking group at Silicon Valley Bank. She sits on the board of directors for the firm’s joint venture in China, SPD Silicon Valley Bank.

    Previously, Ms. Anderson was a senior vice president at Wells Fargo Bank, leading life sciences business development and relationship management efforts for the New England region. Before that, she was a director at Wells Fargo Capital Finance, where she focused on front-end business development and underwriting structured loans. Prior to that she held positions in mergers and acquisitions, finance, equity derivatives, audit, and management at Affiliated Managers Group, Merrill Lynch, General Electric, and GE Capital. Ms. Anderson has a bachelor’s degree in finance and economics from Virginia Tech, and completed the executive leadership and strategic impact program at the Tuck School of Business at Dartmouth.

    Nathan Bush
    Head of Investigations, Asia
    Head of Antitrust & Competition, Asia
    DLA Piper

    Nathan Bush is head of investigations and head of antitrust and competition for DLA Piper in Asia, where he advises clients in internal investigations, government enforcement actions, and compliance matters involving competition, corruption, national security, and international trade. He handles internal investigations and enforcement actions involving violations of the U.S. Foreign Corrupt Practices Act and other laws, as well as securities fraud, market misconduct, money laundering, export controls, and sanctions violations.

    Chambers Asia Pacific recognized Mr. Bush as a leading lawyer in 2019. He co-chairs the Legal and IP Committee of the U.S. Chamber of Commerce in Singapore, and previously served as Legal Committee chairman and general counsel for the organization in China. He has a bachelor’s degree in government and foreign affairs and East Asian studies from the University of Virginia, and a juris doctor degree from Harvard Law School.

    Brendan Griffin Brendan Griffin
    SVB Leerink

    Brendan Griffin brings years of experience advising U.S., Asian, and European Union companies in the biopharmaceutical and life sciences sectors to his role in the investment banking department at SVB Leerink. He has completed more than 100 equity, equity-linked, and advisory transactions, including more than 20 initial public offerings, and has helped companies raise over $15 billion in equity capital.

    Mr. Griffin has a bachelor’s degree from Elon University, a master of business administration degree from Carnegie Mellon University’s Tepper School of Business, and a master’s degree in public policy management from the Heinz School of Public Policy at Carnegie Mellon.

      Frank Jiang
    Portia Ku Portia Ku
    O'Melveny & Myers LLP

    Portia Ku is a corporate transactional lawyer specializing in capital markets, mergers and acquisitions, venture capital, and private equity financing. Her clients include public and private companies spanning a variety of industries, including technology, life sciences, healthcare, and financial services. She has successfully completed a myriad of deals, applying her technical experience, strategic execution, and dedication to guide clients through highly complex transactions.

    Previously, Ms. Ku worked at Cravath, Swaine, & Moore. She has been recognized for her work in capital markets and private equity by International Financial Law Review. She has a bachelor’s degree in law from National Taiwan University and a master of laws degree from Yale University.

    Judith Li

    Lilly Asia Ventures

    Judith Li is a partner at Lilly Asia Ventures, based in Hong Kong and Shanghai. She focuses on early and growth-stage investments across biopharmaceuticals, medical devices, and diagnostics, domestically and cross-border. She holds board appointments at several of the firm’s portfolio companies, including Nextcure, Gritstone Oncology, and Tmunity.

    Previously, Ms. Li worked at McKinsey in New York and in hospital administration at Partners Healthcare. Before that, she was the co-founder of Vasculogic, an interventional nephrology medical device venture. She has a bachelor’s degree in neurobiology from Harvard University and a master of business administration degree from Harvard Business School.

    Qiang Li
    Co-Regional Managing Partner, Asia
    Co-Country Managing Partner, China
    DLA Piper

    Qiang Li is the co-regional managing partner, Asia, for the global law firm of DLA Piper. He advises multinational and Chinese corporate and private equity clients on their cross-border M&A, corporate finance and direct investment projects, and services a number of the firm’s strategic life sciences and healthcare clients, including Charles River Laboratories, Dexcom, Sanpower Group, China Grand Enterprises, and Sinocare.

    Previously, Mr. Li worked at O’Melveny & Myers and Freshfields Bruckhaus Deringer. He frequently counsels international investors on China’s foreign investment legal regime and has served as counsel to the board of the American Chamber of Commerce in Shanghai. He is the founder of the Shanghai-based Global History Club. Mr. Li has a bachelor’s degree in high energy physics from Syracuse University, a master’s degree in physics from New York University, and a juris doctor degree from Columbia Law School.

      Howard Liang
    CFO & CSO
      George Leondis
    President & CEO
    Argon Medical Devices
    Kevin Longo
    Managing Director
    Silicon Valley Bank 

    Kevin Longo is Northeast head of Silicon Valley Bank’s medical device and healthtech divisions. He and his team focus on providing comprehensive financial products and services as well as flexible lending solutions to clients at every stage of development. He is responsible for developing new relationships and overseeing continued growth.

    Previously, Mr. Longo held a variety of positions at Silicon Valley Bank, working with technology and life sciences companies in medical devices, digital health, biotechnology, diagnostics, software, and hardware, from early and pre-venture capital startups to high growth international public companies. He has a bachelor’s degree from Hofstra University.

      Jade Lu
    SVB Asia, SPD Silicon Valley Bank

    Pony Lu
    VISEN Pharma 

    With 28 years of experience in the pharmaceutical market in China, Hong Kong, Taiwan, and Europe, Pony Lu is the chief executive of VISEN Pharmaceuticals, a joint venture between Ascendis Pharma and Vivo Capital. VISEN focuses on endocrine-related disease therapy.

    Previously, Mr. Lu held various roles at Takeda China Holdings, including China general manager and area head of Greater China. Before that, he worked for Servier in Taiwan, China, and France. He started his career at Astra-Zenica in Taiwan. Mr. Lu holds a bachelor’s degree in pharmacy from Taipei Medical University.

    James McGregor

    James McGregor
    Greater China Chairman
    APCO Worldwide

    James McGregor has lived in China for 30 years. He is chairman for Greater China at APCO Worldwide and a well-known writer and speaker about China. He is the author of two books, No Ancient Wisdom, No Followers: The Challenges of Chinese Authoritarian Capitalism and One Billion Customers: Lessons from the Front Lines of Doing Business in China.

    Previously, Mr. McGregor was the chief executive officer of Dow Jones in China and the founder of a China-focused research and advisory firm for hedge funds. Before that he was a journalist for Knight-Ridder and The Wall Street Journal, and was chairman of the American Chamber of Commerce in China. Mr. McGregor is a member of the Council on Foreign Relations, the National Committee on U.S.-China Relations, the Global Council of the Asia Society, and is on the board of the U.S.-China Education Trust. He has a bachelor’s degree in journalism from the University of Minnesota.

      Dave Rank
    Senior Advisor
    The Cohen Group
    Jackie Spencer
    Silicon Valley Bank

    Jackie Spencer is a director at Silicon Valley Bank in San Francisco. She provides banking services and debt-financing solutions to life science companies at all phases, from early-stage venture-backed enterprises to late-stage public companies, using her network to help make pivotal connections for her clients. Her goal is to help visionary companies flourish so they can get new therapeutics in the hands of doctors to improve patient outcomes.

    Previously, Ms. Spencer worked in the bank’s technology practice, first as an associate and later as a vice president, providing resources and tools to help enterprise and consumer application companies in the Bay Area scale their businesses. She has a bachelor’s degree in business and finance from Saint Mary's College of California.

    Chen Yu
    Managing Partner
    Vivo Capital

    Chen Yu, MD, is a managing partner at Vivo Capital, where he invests in private and public pharmaceutical and medical device companies in the U.S. and China.

    Prior to joining Vivo Capital, Dr. Yu held leadership roles at companies including Sagent Pharmaceuticals, China KangHui, and aQuantive. He has played a leading role in facilitating cross-border deals between emerging market and U.S. healthcare companies. He serves on the California Leadership Council for the Nature Conservancy and the Fund Development Committee for the California chapter of the Alzheimer’s Association, and was a member of the Stanford Medical School Alumni Board of Governors. Dr. Yu has a bachelor’s degree in biology from Harvard University, and doctor of medicine and master of business administration degrees from Stanford University.
    Ian Woo Ian Woo
    President & CFO
    Everest Medicines 

    Ian Woo brings more than 18 years of biopharmaceutical and mergers and acquisition experience to his role as president and chief financial officer at Everest Medicines, where he is expanding the company’s efforts to license, develop, and commercialize a broad portfolio of products in China and other Asian markets.

    Previously he was a managing director at the healthcare private equity firm C-Bridge Capital, which was the founding investor in Everest Medicines. Before that, he was a managing director in the global healthcare group at Lazard, where he covered global biopharma companies and led Lazard’s healthcare efforts in China. Mr. Woo has a bachelor’s degree in biology from Tufts University, a master’s degree in molecular and cellular biology from Columbia University, and a master of business administration degree from Columbia Business School.
      Stella Xu
    Quan Capital
      Jing Zhao
    Refuge Biotech
      Jielun Zhu


    Carolyn Bigg Carolyn Bigg
    DLA Piper

    Carolyn Bigg is a partner at DLA Piper and an experienced technology and communications lawyer with a focus on data protection, data retention, and data security law across Asia Pacific. She advises on all forms of technology and communications matters, and has significant experience acting for both users and suppliers in the life sciences, technology, telecommunications, banking, and insurance sectors.

    Ms. Bigg regularly advises global businesses on best practices for managing regional and international data privacy and cyber security compliance across a variety of multi-jurisdictional data privacy projects and international data transfers. She has industry and in-house experience handling client secondments for an international telecoms operator, a U.S. software firm, a forensic service provider, and a global insurer.

    Johnny Choi Johnny Choi
    DLA Piper

    Johnny Choi is a partner at DLA Piper, where he is the head of the firm’s China employment practice. He specializes in complex and strategic employment advice for multinational clients at the C-suite level, including international human resources projects, large scale layoffs and restructurings, cross-border secondments, employee data privacy, human resources investigations, litigious employment disputes, and contentious removal of company executives. He works with international and regional clients in technology, life sciences, financial services, and retail.

    Previously, Mr. Choi worked at Simmons & Simmons, TransAsia Lawyers, and Herbert Smith Freehills. Chambers Asia Pacific has recognized him for his expertise in employment law in the People’s Republic of China. China Business Law Journal named him to its A-list of elite lawyers. He has bachelor’s degrees in law and commerce from the University of New South Wales.
    Sammy Fang Sammy Fang
    DLA Piper

    Sammy Fang is a partner in DLA Piper's litigation and regulatory group in Hong Kong. His specialty is compliance and investigations, which range from proactive compliance reviews, compliance program designs, and enhancement to specialist investigations (internal fraud investigations, anti-bribery and anti-corruption, cyber security, cybercrime, etc.) and product liability and regulatory compliance.

    Mr. Fang is trusted by clients for his deep knowledge of local regulatory regimes and strong experience in the life sciences sector in China. He has been admitted as a solicitor in Hong Kong and the state of New South Wales in Australia.
    Skip Fisher William (Skip) Fisher
    China Head Patents
    DLA Piper

    William (Skip) Fisher is the China Head of Patents within the Intellectual Property and Technology team, based in DLA Piper's Shanghai office. He has practiced IP law in the U.S., China and internationally for 20 years. His practice focuses on counseling, licensing, and enforcement/litigation in all areas of intellectual property, with a particular emphasis on patents, trade secrets and international IP and technology-related transactions.

    Mr. Fisher works with clients to establish and implement strategies for procuring, protecting, commercializing and enforcing their IP rights and for minimizing risk to their IP assets in China, the U.S. and globally. He also counsels clients on U.S., Chinese and international IP law, practice and strategy; represents them in challenging, high-stakes patent, trade secret and other IP litigation and enforcement actions; and assists them in negotiating and drafting IP licenses, collaboration and development contracts and other commercial agreements.
    Windson Li Windson Li
    Head of Tax Group
    DLA Piper

    With more than 18 years of experience in Chinese corporate law and taxes, international taxes, and transfer pricing services, Windson Li is a certified tax agent and head of the tax group at DLA Piper's Beijing office. He provides corporate, legal, and cross-border tax consulting services to international companies and high-net-worth clients, with a focus on mergers and acquisitions, company formation, joint ventures, tax structures, business model transitions, transfer pricing, and trust formation of enterprises in China and abroad. Mr. Li advises clients across a wide range of sectors and industries and is a member of the People’s Republic of China bar.
    Scott Thiel Scott Thiel
    Intellectual Property & Technology Practice Location Head
    DLA Piper

    Scott Thiel is the location head of the Intellectual Property and Technology practice at DLA Piper in Hong Kong. He specializes on technology transactions and has a background in engineering and computer science. He is a co-leader of the firm’s distributed ledger, blockchain, and digital assets practice, an area increasingly used in the validation and exchange of healthcare information.

    Mr. Thiel advises a broad range of clients on information, data privacy, data commercialization, telecoms, and cybersecurity issues across multiple jurisdictions, including Greater China, the U.S., Southeast Asia, South Korea, Japan, and the European Union. His clients are in technology, banking, transportation, pharmaceuticals, life sciences, energy, and sports. He has bachelor’s degrees in computer science, physics, and law from the University of Melbourne and a master of laws degree in intellectual property from Monash University.

    Stewart Wang Stewart Wang
    DLA Piper

    Stewart Wang is a partner on the corporate team in DLA Piper's Shanghai office, where he focuses on cross-border mergers and acquisitions, private equity, venture capital, foreign direct investments, joint ventures, debt financings, employment matters, and dispute resolution. He represents multinational companies and China-based clients in industries including technology, media, communications, manufacturing, pharmaceutical, medical devices, aerospace, and real estate.

    Previously, Mr. Wang worked for O’Melveny & Myers and Freshfields Bruckhaus Deringer. China Business Law Journal named him to its A-list of elite lawyers. He has master of laws degrees from the University of Sheffield and New York University.
    Ting Xiao Ting Xiao
    Senior Associate
    DLA Piper

    Ting Xiao is a senior associate in the intellectual property and technology practice of DLA Piper's Shanghai office, where she focuses on patents and other technology-related matters. She specializes in licensing and technology transfer, commercial transactions, regulatory and compliance work, and IP enforcement and litigation matters. She frequently advises on regulatory issues relating to the biotechnology, pharmaceutical, medical devices, and healthcare industries.

    Previously, Ms. Xiao was a research scientist at the National Key Laboratory at the Chinese Academy of Sciences and at a renowned drug discovery organization in Canada. Her work has appeared in Nature Methods and other publications. Managing Intellectual Property magazine named her a rising star in IP. She has a bachelor’s degree in biology technology from Wuhan University and a master’s degree in medical biophysics and a juris doctor degree from the University of Toronto.

Presented By

Platinum Sponsors

Silver Sponsors


Be the first to get updates on HCCS and SVB’s other China cross-border activities.

China Healthcare Investment Conference and the sponsors listed above are unaffiliated with SVB Financial Group. 

This material including without limitation to the statistical information herein, is provided for informational purposes only. The material is based in part on information from third-party sources that we believe to be reliable, but which have not been independently verified by us and for this reason we do not represent that the information is accurate or complete. The information should not be viewed as tax, investment, legal or other advice nor is it to be relied on in making an investment or other decision. You should obtain relevant and specific professional advice before making any investment decision. Nothing relating to the material should be construed as a solicitation, offer or recommendation to acquire or dispose of any investment or to engage in any other transaction.